RecruitingBiliary Tract CancerBreast CancerCervical Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
You may qualify if…
- ✓ Patients must be ≥ 18 years of age
- ✓ Histologically or cytologically confirmed diagnosis of metastatic solid tumors
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- ✓ All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
- ✓ All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- ✓ Adequate hematologic, hepatic and renal function
- ✓ Capable of giving signed informed consent
You may not qualify if…
- ✕ Any clinically significant cardiac disease
- ✕ Unresolved toxicities from previous anticancer therapy
- ✕ Prior solid organ or hematologic transplant
- ✕ Known untreated, active, or uncontrolled brain metastases
- ✕ Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectiion requiring intravenous treatment.
- ✕ Receipt of a live-virus vaccination within 28 days of planned treatment start
- ✕ Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.
- ✕ Participation in a concurrent clinical study in the treatment period.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06239194 · last updated 2026-05-06